The Dundalk site was WuXi's first manufacturing investment in Europe and the company’s first investment of this scale outside of China ...

WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025, the deal ...

News that pharmaceutical company MSD Ireland has acquired the WuXi Vaccines manufacturing facility in Dundalk has been ...

WuXi 2269-1.25%decrease ... The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late ...

Merck's €500 million investment in Dundalk adds to €3 billion invested ... Over 3,000 people are employed across the network. Merck and WuXi Vaccines are now entering a formal handover process ...

The pharmaceutical firm MSD is buying out the WuXi Vaccines manufacturing plant in Dundalk, in a €500m deal. The American company says that in addition to the 150 jobs at the Dundalk facility ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Pharmaceutical firm MSD has agreed a deal to buy the WuXi Vaccines manufacturing facility in Dundalk, Co Louth as part of its long-term plans in Ireland. MSD said the deal is worth €500m and ...

The employees at WuXi Biologics have once again shown their commitment to the local community with their fourth annual Christmas appeal for the St. Vincent de Paul Society in Dundalk. Continuing ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025 ...